The New York Entrepreneur

Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says

Read Time:7 Second

The study results on Leqembi, which Eisai shares with Biogen, also found that Alzheimer’s patients who take the therapy get worse after they stop treatment.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post Pinterest shares tumble nearly 15% on weak guidance
Next post Tinder parent Match sees ‘transformation’ for the dating app, which has been losing users